uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform
Show others and affiliations
2013 (English)In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 19, no 18, 5210-5217 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: Paclitaxel is used in the treatment of solid tumors and displays high interindividual variation in exposure. Low paclitaxel clearance could lead to increased toxicity during treatment. We present a genetic prediction model identifying patients with low paclitaxel clearance, based on the drug-metabolizing enzyme and transporter (DMET)-platform, capable of detecting 1,936 genetic variants in 225 metabolizing enzyme and drug transporter genes. Experimental Design: In 270 paclitaxel-treated patients, unbound plasma concentrations were determined and pharmacokinetic parameters were estimated from a previously developed population pharmacokinetic model (NONMEM). Patients were divided into a training-and validation set. Genetic variants determined by the DMET platform were selected from the training set to be included in the prediction model when they were associated with low paclitaxel clearance (1 SD below mean clearance) and subsequently tested in the validation set. Results: A genetic prediction model including 14 single-nucleotide polymorphisms (SNP) was developed on the training set. In the validation set, this model yielded a sensitivity of 95%, identifying most patients with low paclitaxel clearance correctly. The positive predictive value of the model was only 22%. The model remained associated with low clearance after multivariate analysis, correcting for age, gender, and hemoglobin levels at baseline (P = 0.02). Conclusions: In this first large-sized application of the DMET-platform for paclitaxel, we identified a 14 SNP model with high sensitivity to identify patients with low paclitaxel clearance. However, due to the low positive predictive value we conclude that genetic variability encoded in the DMET-chip alone does not sufficiently explain paclitaxel clearance. 

Place, publisher, year, edition, pages
2013. Vol. 19, no 18, 5210-5217 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-209867DOI: 10.1158/1078-0432.CCR-13-0487ISI: 000324513000031OAI: oai:DiVA.org:uu-209867DiVA: diva2:659867
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 31-JUN 04, 2013, Chicago, IL, USA
Available from: 2013-10-28 Created: 2013-10-28 Last updated: 2013-10-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Friberg, Lena E.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Clinical Cancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 218 hits
ReferencesLink to record
Permanent link

Direct link